Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Rhea-AI Summary

Cuprina Holdings (Nasdaq: CUPR) received a Nasdaq noncompliance notice dated November 26, 2025 for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2).

Cuprina has an initial 180-calendar-day compliance period to regain the $1.00 closing bid for at least ten consecutive business days. If not regained, the company may be eligible for a second 180-day period by meeting market value and other initial listing standards (excluding the bid price) and providing written notice to cure, potentially by effecting a reverse stock split. Shares will continue to trade uninterrupted under the symbol CUPR while the process unfolds. Cuprina is evaluating options to regain compliance but stated there is no assurance it will do so.

Positive

• Nasdaq notice dated Nov 26, 2025
• Initial 180-calendar-day compliance period
• Requirement: $1.00 closing bid for 10 consecutive business days
• Shares continue trading under CUPR

Negative

• Currently noncompliant with Nasdaq $1.00 minimum bid
• Risk of delisting if deficiency is not cured within compliance periods
• May need a reverse stock split to regain compliance
• Company states no assurance it will regain compliance

Insights

Listing Compliance Specialist

Nasdaq notified Cuprina of a $1 minimum bid-price deficiency; company has a 180 calendar days cure window.

Cuprina faces a technical listing deficiency under Nasdaq Rule 5550(a)(2) because the closing bid was below $1 for the past 30 business days, per the notice dated Nov. 26, 2025. The company retains normal trading status while it pursues compliance and must achieve a closing bid at or above $1 for ten consecutive business days within the initial 180 calendar days to close the matter.

The main operational dependency is whether the company can restore its bid price within the cure period or qualify for the second compliance period by meeting market value and other initial listing standards and filing intent to cure, potentially via a reverse stock split. Key near-term items to watch are daily closing bid progression, any announced reverse split authorization, and the formal written confirmation from Nasdaq if the ten-day condition is met; expect developments within the next 180 calendar days.

Investor Relations Strategist

The notice is a negative listing-risk event but does not trigger immediate delisting; investor communication will shape market reaction.

Market perception will hinge on clear, timely disclosure and a concrete remediation plan. The firm states it intends to regain compliance but provides no specific actions or timelines beyond the regulatory cure periods, leaving uncertainty about the chosen path such as a reverse split or other measures to raise the trading price.

Stakeholders should monitor formal filings, announcements on capital structure changes, and any Nasdaq confirmations; absence of decisive action within the initial 180 calendar days increases the probability of entering a second compliance period or receiving a delisting notice, so updates in that timeframe are the most material.

SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of noncompliance from The Nasdaq Stock Market LLC ("Nasdaq"), dated November 26, 2025, notifying the Company that based on Cuprina’s closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.

However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide Cuprina with written confirmation of compliance and this matter will be closed.

In the event the Company does not regain compliance, Cuprina may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Cuprina meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its securities will be subject to delisting.

The Nasdaq notification letter does not result in the immediate delisting of the Company's ordinary shares, and the shares will continue to trade uninterrupted under the symbol "CUPR." 

Cuprina is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although Cuprina will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com. 

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5^th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com

FAQ

What did Cuprina (CUPR) receive from Nasdaq on November 26, 2025?

A Nasdaq noncompliance notice for failing to meet the $1.00 minimum bid under Rule 5550(a)(2).

How long is Cuprina's initial compliance period to regain Nasdaq listing (CUPR)?

Cuprina has an initial 180-calendar-day period to regain compliance.

What price requirement must CUPR meet to regain Nasdaq compliance during the 180-day period?

A closing bid of at least $1.00 for a minimum of 10 consecutive business days.

Will Cuprina (CUPR) be delisted immediately after the Nasdaq notice?

No. The notice does not cause immediate delisting and shares will continue trading under CUPR.

What can Cuprina do if it fails to regain compliance in the first 180 days?

It may seek an additional 180-calendar-day period by meeting market value and other initial listing standards and notifying Nasdaq, potentially via a reverse stock split.

Does Cuprina guarantee it will regain Nasdaq compliance (CUPR)?

No. The company stated it will try to regain compliance but provided no assurance it will succeed.